










AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in this application.









Listing of Claims:
















1. (Withdrawn) A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:


943		
944		
945		
946		
947		
948		
949		



963		chiral (+)
964		CHIRAL
965		CHIRAL
966		CHIRAL
967		CHIRAL
968		
969		
970		
971		
972		
973		
974		chiral (+)
975		chiral (+)

976	
977	
978	 <p>chiral (-)</p>
979	 <p>chiral (+)</p>
980	
981	
982	
983	
984	
985	
986	

987		994	
988		995	
989		996	
990		997	
991		998	
992		999	
993		1000	
		1001	



2. (Withdrawn) A pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of a compound according to claim 1 in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.
3. (Withdrawn) The pharmaceutical formulation according to claim 2, for use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
4. (Withdrawn) A compound according to claim 1 for use in therapy.
5. (Withdrawn) The compound according to claim 1, for use in prevention and/or treatment of mGluR5 receptor-mediated disorders.
6. (Withdrawn) The compound according to claim 5, wherein the disorder is a neurological disorder.
7. (Withdrawn) The compound according to claim 5, wherein the disorder is a psychiatric disorder.



8. (Withdrawn) The compound according to claim 5, wherein the disorder is selected from chronic and acute pain disorders.













9. (Withdrawn) The compound according to claim 5, wherein the disorder is a gastrointestinal disorder.













10. (Withdrawn) The compound according to claim 5, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases, GERD, and epilepsy.



11. (Withdrawn - Currently Amended) A method of manufacturing The use of a compound according to claim 1 in the manufacture of a medicament for the use in the prevention and/or treatment of mGluR5 receptor-mediated disorders comprising a compound according to claim 1.















12. (Currently Amended) A method of ~~prevention and/or treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such prevention and/or treatment a therapeutically effective amount of a compound, according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:~~




<u>954</u>		<u>961</u>	
<u>955</u>		<u>962</u>	
<u>956</u>		<u>963</u>	
<u>957</u>		<u>964</u>	
<u>958</u>		<u>965</u>	
<u>959</u>			
<u>960</u>			

<u>966</u>	CHIRAL 	<u>973</u> 
<u>967</u>	CHIRAL 	<u>974</u>  <u>chiral (+)</u>
<u>968</u>		<u>975</u>  <u>chiral (+)</u>
<u>969</u>		
<u>970</u>		<u>976</u> 
<u>971</u>		
<u>972</u>		<u>977</u> 



<u>990</u>		
<u>991</u>		
<u>992</u>		
<u>993</u>		
<u>994</u>		
<u>995</u>		
<u>996</u>		
<u>997</u>		
<u>998</u>		
<u>999</u>		
<u>1000</u>		
<u>1001</u>		
<u>1002</u>		
<u>1003</u>		



wherein the disorder is selected from the group consisting of neurological disorders, psychiatric disorders, chronic and acute pain disorders, gastrointestinal disorders, Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

13. (Original) The method according to claim 12, wherein the disorder is a neurological disorder.

14. (Original) The method according to claim 12, wherein the disorder is a psychiatric disorder.

15. (Original) The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders.

16. (Original) The method according to claim 12, wherein the disorder is a gastrointestinal disorder.

17. (Original) The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

18. (Withdrawn) A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1.